For Anti Cancer Immunotherapy Articles & Analysis: Older
139 news found
During the event, the team demonstrated their pipeline from phage construction to screening and their masterpiece in discovering PTM specific antibodies, anti-idiotype antibodies, which gives researchers an edge when looking to discover novel targets in immunotherapy, cancer, and infectious diseases. ...
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer ...
ByTempus
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of ...
ByOncoVITA
CD Genomics, an excellent leader in genomics and bioinformatics, has unveiled a groundbreaking leap forward in TCR-Seq technology, poised to revolutionize immune repertoire profiling. With an unwavering commitment to innovation and precision, CD Genomics continues to redefine the genomics research landscape. TCR-Seq, short for T Cell Receptor Sequencing, is an instrumental tool that enables ...
Scientists can utilize these antibodies to study how herpesviruses enter cells, facilitating the development of new antiviral drugs. For example, the Anti-HSV 2 monoclonal antibody (Catalog # CABT-B9084), which reacts with herpes simplex virus type 2 (HSV2) and is specific for the viral glycoprotein D (gD) protein. ...
These data were published in an abstract by the Society for Immunotherapy of Cancer (SITC) and will be presented in a poster presentation today at the 37th Annual SITC Meeting in Boston, MA. ...
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent ...
BRYAN, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,545,238, entitled “Machine Learning Method For Protein Modelling To Design Engineered Peptides,” which ...
Antengene is proud to announce that the oral presentation for ATG-031 (anti-CD24 monoclonal antibody) presented at the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022) was selected for the SITC top 100 abstracts. ATG-031 is a first-in-class, humanized anti-CD24 antibody. ATG-031 potently binds to ...
Ardigen, one of the world’s leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board. Her knowledge and experience will support a deeper understanding of active cancer immunotherapies in the drug discovery process provided by scientific innovation. Mariola ...
ByArdigen
New York, New York, November 10, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and ...
” “Additionally, we are excited to announce that Beyond Cancer’s first-in-human Phase 1 study of UNO for the treatment of solid tumors designed to assess safety and efficacy is moving along after the first patient was treated in August 2022. ...
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. According to the official speaker from Creative BioMart, based on MHC-like complexes that can ...
Therefore, inhibiting HPK1 activity serves as a promising approach for cancer immunotherapy. Currently, there is no HPK1 inhibitor approved globally. The phase 1 clinical trial is the first-in-human (FIH) study of RGT-264 phosphate tablet, aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary anti-tumor activity of ...
CD Genomics, a world-leading company in genomic services, today announced that members of its management team would participate in the 37th Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in Boston, MA, November 8-12, 2022. Details for the 37th Annual Meeting & Pre-Conference Programs (SITC 2022) The 37th Annual Meeting & Pre-Conference Programs (SITC 2022) provides a ...
The data, including studies presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting & Pre-conference Programs in November 2021, has demonstrated that the combination of an ERK1/2 inhibitor and an immune checkpoint inhibitor (ICI) worked synergistically to produce improved efficacy in preclinical ICI-resistant in vivo mice models. ...
(“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12. The posters will highlight preclinical studies on five ...
Chiles Research Institute, Providence Cancer Institute, Portland, Oregon. “Currently, 70-80 percent of cancer patients with solid tumors do not achieve durable responses to T-cell checkpoint therapies alone, and people with many types of cancer have yet to benefit from the promise of this class of immunotherapy. ...
(KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company’s first immuno-oncology drug candidates, at SITC (Society for Immunotherapy of Cancer) Annual Meeting taking place November 8-12 in Boston. ...
This supports the clinical development plan to advance IO-108 into select cancers for dose expansion as monotherapy and in combination with anti-PD-(L)1 and/or standard of care therapies. ...